drugset / Trial / NCT02275663
Azacytidine Plus FLAG for Relapsed or Refractory AML
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this phase 2 study is to test the efficacy of azacytidine given prior to fludarabine, cytarabine, and G-CSF for the treatment of relapsed or refractory acute myeloid leukemia.
Timeline
- Start
- 2014-12
- Primary completion
- 2017-10
- Completion
- 2018-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacytidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 2 g | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |